Liquidia reports Q3 2026 sales surge for YUTREPIA and resolves major litigation with United Therapeutics.

Liquidia Technologies reported $222.7 million in net sales for its inhaled powder drug YUTREPIA in Q3 2026, a 31% increase from the previous quarter, with patient shipments hitting record levels. The company resolved all litigation with United Therapeutics through a $389.7 million settlement, securing uninterrupted patient access to YUTREPIA. Despite a net loss of $236.3 million mainly due to the settlement charge, Liquidia posted its fifth consecutive quarter of rising adjusted EBITDA at $140.5 million. The company is advancing clinical trials for YUTREPIA and its pipeline drug L606, aiming to expand treatments for pulmonary arterial hypertension and related conditions.

Following Liquidia Technologies' third quarter report highlighting strong sales growth and a major settlement, its stock price on Pluang is USD 48.00 as of Nov 10, 2026 18:11 WIB, showing a modest 0.27% increase for the day. The company holds a market capitalization of $4.28 billion on the platform, with most Pluang users currently selling the stock at 97% sell activity. This trading behavior occurs despite the recent positive operational results and ongoing clinical advancements.